In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Lilly licenses Amylin's diabetes drug; deal ends with rights returned to Amylin

Executive Summary

Eli Lilly will collaborate on further clinical development and commercialization of Amylin Pharmaceuticals' (treatments for diabetes and other metabolic diseases) AC2993 (exenatide), a Phase III candidate for Type II diabetes.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • Co-Promotion
    • Includes Contract
    • Product or Technology Swap
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies

UsernamePublicRestriction

Register